乌帕替尼与TNFi治疗类风湿关节炎的持续性与有效性:加拿大与瑞士注册研究汇总分析
ROSA研究基于加拿大RHUMADATA、OBRI及瑞士SCQM三个注册库,纳入990例2020年1月至2023年6月启动乌帕替尼或TNFi的RA患者,采用多重插补和倾向评分校正。乌帕替尼停药风险低于TNFi(HR 0.602,95%CI 0.469–0.773),且不受既往进阶治疗影响;两组6个月和12个月CDAI低疾病活动度或缓解比例无显著差异。
要点
- 乌帕替尼较TNFi停药风险更低(HR 0.602,95%CI 0.469–0.773)。
- 联用csDMARD或甲氨蝶呤可改善两组持续用药。
- 6个月和12个月CDAI低疾病活动度或缓解比例两组无显著差异。
核心结论
- 加拿大与瑞士RA患者中,乌帕替尼的用药持续性优于TNFi,且不受既往进阶治疗暴露影响。
研究设计与样本
- 观察性研究分析990例RA患者,数据来自加拿大RHUMADATA、OBRI及瑞士SCQM注册库,纳入2020年1月1日至2023年6月30日启动乌帕替尼或TNFi者。
- 采用多重插补处理基线协变量缺失,并依据预设变量(年龄、病程、既往治疗、合并症等)计算的倾向评分进行校正。
主要发现
- 乌帕替尼组停药风险低于TNFi组,HR(95%CI)为0.602(0.469,0.773),且不受既往进阶治疗影响。
- 联用任何csDMARD与改善持续性相关:乌帕替尼HR(95%CI)0.225(0.107,0.471),TNFi HR(95%CI)0.516(0.303,0.881)。
- 联用甲氨蝶呤与改善持续性相关:乌帕替尼HR(95%CI)0.604(0.390,0.934),TNFi HR(95%CI)0.694(0.522,0.925)。
- 6个月时乌帕替尼组与TNFi组达到CDAI低疾病活动度或缓解的比例分别为70.8%与61.0%(P=0.1541)。
- 12个月时乌帕替尼组与TNFi组达到CDAI低疾病活动度或缓解的比例分别为70.5%与75.2%(P=0.4494)。
临床怎么用
- 在RA治疗选择中,乌帕替尼可能较TNFi提供更优的用药持续性,尤其需考虑长期维持治疗时。
- 无论选择乌帕替尼还是TNFi,联用csDMARD或甲氨蝶呤均与更好的持续用药相关。
- 乌帕替尼与TNFi在6个月和12个月疾病活动度控制方面未显示显著差异,需结合患者个体情况综合决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The ROSA study evaluated real-world persistence and effectiveness of upadacitinib and tumour necrosis factor inhibitors (TNFi) in patients with rheumatoid arthritis (RA), using data from two Canadian registries, RHUMADATA and Ontario Best Practices Research Initiative (OBRI), and the Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry. METHODS: This observational study analysed data from 990 patients with RA who initiated upadacitinib or TNFi between 1 January 2020 and 30 June 2023. Multiple imputation was used for baseline covariates with missing data and results were adjusted for propensity scores derived from pre-specified variables (age, disease duration, prior treatments, comorbidities, etc.). Persistence was assessed using Kaplan-Meier and Cox proportional hazard regression models. Effectiveness was evaluated using observed (non-imputed) disease activity indices over 6 and 12 months. RESULTS: Overall, 174, 216 and 600 patients were included from the RHUMADATA, OBRI, SCQM registries, respectively. Patients using upadacitinib had a lower risk of discontinuing treatment than patients using TNFi [hazard-ratio (HR) (95% CI): 0.602 (0.469, 0.773)] and this was unaffected by previous exposure to advanced treatment. Concomitant use of any csDMARD HR (95% CI); [upadacitinib: 0.225 (0.107, 0.471); TNFi: 0.516 (0.303, 0.881)], and methotrexate [upadacitinib: 0.604 (0.390, 0.934); TNFi: 0.694 (0.522, 0.925)] were associated with improved persistence for both groups. A similar proportion of patients receiving upadacitinib or TNFi achieved Clinical Disease Activity Index low disease activity or remission at 6 months (70.8% vs 61.0%; P = 0.1541) and 12 months (70.5% vs 75.2%; P = 0.4494). CONCLUSION: Canadian and Swiss patients with RA had longer persistence with upadacitinib than TNFi, independent of previous advanced treatments.
引用
- Choquette D, Finckh A, Rubbert-Roth A, et al. Persistence and effectiveness of upadacitinib and TNFi for rheumatoid arthritis using pooled data from Canadian and Swiss registries. Rheumatology (Oxford). 2026. PMID: 42334951. doi:10.1093/rheumatology/keag301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。